{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:45:52Z","timestamp":1768275952140,"version":"3.49.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2018J01391"],"award-info":[{"award-number":["2018J01391"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Acute promyelocytic leukemia (APL) is one of the most curable cancers. However, relapse of the disease is a difficult issue in clinical practice and it remains a great challenge that patients have a poor effect of conventional treatment in the clinic. Therefore, new and more effective therapeutic measures are urgently needed. Herein, we report a case of relapsed and refractory APL harboring a RARA-LBD region mutation successfully treated with venetoclax (VEN).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 37-years-old woman was admitted to our hospital with worsening spontaneous gingival bleeding and skin ecchymosis. Physical examination revealed multiple petechiae and ecchymosis in the extremities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient was diagnosed with L-type PML-RAR\u03b1-positive APL, harboring a RARA-LBD region mutation, low-risk, based on bone marrow cytology, immunophenotypic analysis by flow cytometry, karyotype analysis, and molecular analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Complete remission was achieved after the first induction therapy of all-trans retinoic acid (ATRA) combined with arsenic trioxide, but relapse was observed only after 11\u200amonths. Reinduction with ATRA and arsenic trioxide combined with anthracycline failed. Therefore, we tried to provide a new treatment with the Bcl-2 inhibitor VEN orally (100\u200amg d1, 200\u200amg d2 to d18, followed by 300\u200amg daily continuously).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Clinical symptoms and laboratory indicators improved rapidly with VEN treatment. A complete hematologic response was achieved with VEN-based therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Related drug resistance gene monitoring should be performed canonically in relapsed and refractory APL. Some relapsed and refractory APL that failed to respond to conventional treatment were at risk of death. Bcl-2 inhibitors are expected to be an effective salvage therapy for patients with resistance to ATRA, which is worthy of further discussion.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028076","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T13:19:17Z","timestamp":1638537557000},"page":"e28076","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Relapsed\/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax"],"prefix":"10.1097","volume":"100","author":[{"given":"Youli","family":"Li","sequence":"first","affiliation":[{"name":"The Third Clinical Medical College, Fujian Medical University, Fuzhou, China"},{"name":"Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieni","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinhong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-8567","authenticated-orcid":false,"given":"Kejie","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Third Clinical Medical College, Fujian Medical University, Fuzhou, China"},{"name":"Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/j.clml.2019.12.011","article-title":"Outcomes in adult acute promyelocytic leukemia: a decade experience","volume":"20","author":"Yedla","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"106314","DOI":"10.1016\/j.leukres.2020.106314","article-title":"Venetoclax combination therapy in relapsed\/refractory acute myeloid leukemia: a single institution experience","volume":"90","author":"Gaut","year":"2020","journal-title":"Leuk Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","article-title":"Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax","volume":"99","author":"Wang","year":"2020","journal-title":"Ann Hematol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.leu.2404006","article-title":"Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy","volume":"20","author":"de Botton","year":"2006","journal-title":"Leukemia"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-017-0404-4","article-title":"High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study","volume":"10","author":"Yoon","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2016.71.6183","article-title":"Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the children's oncology group phase iii historically controlled trial AAML0631","volume":"35","author":"Kutny","year":"2017","journal-title":"J Clin Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2018-05-851824","article-title":"Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial","volume":"132","author":"Russell","year":"2018","journal-title":"Blood"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"112446","DOI":"10.1016\/j.ejmech.2020.112446","article-title":"Single and dual target inhibitors based on Bcl-2: promising anti-tumor agents for cancer therapy","volume":"201","author":"Liu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","article-title":"ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia","volume":"121","author":"Vandenberg","year":"2013","journal-title":"Blood"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00277-015-2477-x","article-title":"Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients","volume":"94","author":"Lou","year":"2015","journal-title":"Ann Hematol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/sj.leu.2404118","article-title":"Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure","volume":"20","author":"Gallagher","year":"2006","journal-title":"Leukemia"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2012-01-407601","article-title":"Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia","volume":"120","author":"Gallagher","year":"2012","journal-title":"Blood"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s41467-018-04384-5","article-title":"Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia","volume":"9","author":"Lehmann-Che","year":"2018","journal-title":"Nat Commun"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.25573","article-title":"Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse","volume":"94","author":"Iaccarino","year":"2019","journal-title":"Am J Hematol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2009.220","article-title":"PML-RARalpha ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL","volume":"24","author":"Schachter-Tokarz","year":"2010","journal-title":"Leukemia"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2011-01-329433","article-title":"Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment","volume":"118","author":"Goto","year":"2011","journal-title":"Blood"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1056\/NEJMc1316382","article-title":"Resistance to arsenic therapy in acute promyelocytic leukemia","volume":"370","author":"Zhu","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:38:13Z","timestamp":1746333493000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028076"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":25,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028076","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]},"assertion":[{"value":"2021-10-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}